Tanaka K, Asahina H, Kishimoto J, Miyata Y, et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. Eur J Cancer 2021;149:14-22.
PMID: 33813328